ACOG Stock Overview
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Alpha Cognition Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.68 |
| 52 Week High | CA$0.99 |
| 52 Week Low | CA$0.19 |
| Beta | 3.36 |
| 1 Month Change | -12.82% |
| 3 Month Change | -24.44% |
| 1 Year Change | 183.33% |
| 3 Year Change | -35.24% |
| 5 Year Change | n/a |
| Change since IPO | -45.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACOG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -5.6% | -1.1% | 0.7% |
| 1Y | 183.3% | -38.2% | 5.5% |
Return vs Industry: ACOG exceeded the Canadian Biotechs industry which returned -37.9% over the past year.
Return vs Market: ACOG exceeded the Canadian Market which returned 6.1% over the past year.
Price Volatility
| ACOG volatility | |
|---|---|
| ACOG Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ACOG's share price has been volatile over the past 3 months.
Volatility Over Time: ACOG's weekly volatility has decreased from 25% to 15% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael McFadden | www.alphacognition.com |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. Fundamentals Summary
| ACOG fundamental statistics | |
|---|---|
| Market cap | CA$102.12m |
| Earnings (TTM) | -CA$18.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs ACOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.77m |
| Earnings | -US$13.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.092 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -25.9% |
How did ACOG perform over the long term?
See historical performance and comparison